Cytodyn Inc (Cytodyn), formerly RexRay Corp, is a biotechnology company. It develops and commercializes monoclonal antibodies for the treatment of Human Immunodeficiency Virus (HIV) infections. It is investigating Leronlimab (PRO 140), a fully humanized IgG4 monoclonal antibody directed against CCR5, to treat HIV. The company is also evaluating its pipeline against triple negative breast cancer, solid tumors, graft vs host disease, non-alcoholic steatohepatitis (NASH), coronavirus and auto immune diseases. CytoDyn uses prostate diagnostic test (PCa test) to determine outcomes of patients diagnosed with prostate cancer. It works in collaboration with pharmaceutical and biotechnology companies to develop its products. The company has operational presence in Florida, the US. Cytodyn is headquartered in Vancouver, Washington, the US.
Headquarters
United States of America
Address
1111 Main St Ste 660, Vancouver, Washington, 98660-2970
Website
www.cytodyn.com
Telephone
1 360 9808524
No of Employees
24
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CYDY (OTC)
EPS
XXX
Net Income (2021)
XXX
-24.3%
(2021 vs 2020)
Market Cap*
$279.7M
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products |
|---|
| Pipeline |
| Leronlimab |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Financing Agreements | In April, the company announced to raise US$1.89 million in equity financing. |
| 2022 | Contracts/Agreements | In January, the company along with Regnum Corp and SevenScore Pharmaceuticals, LLC entered into a commercialization and license Agreement to commercialize leronlimab (PRO 140) in the U.S. for the treatment of HIV from SevenScore to Regnum. |
| 2021 | Regulatory Approval | In December, the company submitted a Phase 3, randomized, double blind, placebo controlled trial with the U.S. Food and Drug Administration (FDA) for phase 3 Registrational trial of Leronlimab for Critically Ill COVID-19 population. |
Competitor Comparison
| Key Parameters | Cytodyn Inc | F. Hoffmann-La Roche Ltd | AbbVie Inc | Merck & Co Inc | Celgene Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | United States of America |
| City | Vancouver | Basel | North Chicago | Whitehouse Station | Summit |
| State/Province | Washington | - | Illinois | New Jersey | New Jersey |
| No. of Employees | 24 | 100,920 | 50,000 | 68,000 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Tanya Durkee Urbach | Chairman | Executive Board | - | - |
| Scott A. Kelly, M.D. | Director; Chief Medical Officer; Head-Business Development | Executive Board | 2020 | 50 |
| Seenu Srinivasan, Ph.D. | Director - CMC Regulatory Affairs | Executive Board | 2021 | - |
| Antonio Migliarese | President - Interim; Chief Financial Officer | Senior Management | 2021 | - |
| Nitya Ray, Ph.D. | Chief Operating Officer | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer